首页 | 本学科首页   官方微博 | 高级检索  
按 检索        


Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma
Authors:Fernando Rivera  Maica Gal??n  Josep Tabernero  Andres Cervantes  Ma Eugenia Vega-Villegas  Javier Gallego  Berta Laquente  Edith Rodr??guez  Alfredo Carrato  Pilar Escudero  Bartomeu Massut??  Vicente Alonso-Ordu?a  Adelaida Cardenal  Alberto S??enz  Jordi Giralt  Ana Lucia Yuste  Antonio Ant??n  Enrique Aranda
Institution:1. Medical Oncology Department, H. U. Marqu??s de Valdecilla, Santander, Spain
12. Medical Oncology Department, Marqu??s de Valdecilla University Hospital, Avda, Valdecilla s/n, 39008, Santander, Spain
2. Medical Oncology Department, ICO L??Hospitalet, Barcelona, Spain
3. Medical Oncology Department, Vall d??Hebron University Hospital, Barcelona, Spain
4. Hematology and Medical Oncology Department, University Hospital, University of Valencia, Valencia, Spain
5. Medical Oncology Department, H. General U, Elche, Alicante, Spain
6. Medical Oncology Department, H. Cl??nico U, Lozano Blesa, Zaragoza, Spain
7. Medical Oncology Department, H. General U, Alicante, Spain
8. Medical Oncology Department, H. Miguel Servet, Zaragoza, Spain
9. Radiotherapy Department, H.U. Marqu??s de Valdecilla, Santander, Spain
10. Radiotherapy Department, Vall d??Hebron University Hospital, Barcelona, Spain
11. Medical Oncology Department, H.U. Reina Sof??a, C??rdoba, Spain
Abstract:

Purpose

The prognosis of patients with unresectable M0 gastric cancer remains very poor. We performed a phase II trial to explore the efficacy and toxicity of induction irinotecan-cisplatin (IC) followed by concurrent irinotecan-cisplatin and radiotherapy (IC/RT) in this setting.

Methods and materials

Patients with unresectable M0 gastric (GC) or oesophageal-gastric junction (EGJC) adenocarcinomas were treated with two courses of IC (irinotecan, 65?mg/m2; cisplatin, 30?mg/m2 on days 1 and 8 every 21?days) followed by IC/RT (daily radiotherapy??45?Gy??with concurrent IC: irinotecan, 65?mg/m2, and cisplatin, 30?mg/m2, on days 1, 8, 15, and 22). Resectability was reassessed after this treatment, and surgical resection was performed if feasible. The primary endpoint was the R0 resection rate after induction treatment.

Results

Seventeen patients were included in the study (EGJC: 6; GC: 11). An R0 resection was achieved in only 5 patients (29%), and according to the design of the trial (Simon??s optimal two-stage) accrual of patients was terminated after the first stage. No patient died during IC, whereas 3 patients (24%) died during IC/RT and one of 5 resected patients (20%) died during the first 30?days after resection. The median survival was 10.5?months, and the actuarial 2-year survival rate was 27%.

Conclusions

Induction IC followed by IC/RT showed poor efficacy and significant toxicity in patients with unresectable GC/EGJC.
Keywords:
本文献已被 SpringerLink 等数据库收录！
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号